Tempus AI (TEM) announced a new strategic collaboration to advance Boehringer Ingelheim’s cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development. With this new collaboration, Boehringer will have access to Tempus’ de-identified database containing molecular, clinical, and imaging data and its analytical platform, Lens. The aim is to explore data derived from patient cohorts to guide biomarker development and patient stratification, develop drug combination hypotheses, support novel target discovery efforts, and educate on patients’ healthcare journey.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI announces six posters accepted for presentation at ISPOR 2025
- Unusually active option classes on open May 9th
- Tempus AI Reports Strong Growth and Strategic Partnerships in Earnings Call
- Tempus AI, Inc.: Mixed Signals Prompt Hold Rating Amid Revenue Growth and Cash Flow Concerns
- Tempus AI price target raised to $65 from $60 at BTIG